003520.KS
Yungjin Pharm. Co., Ltd. [003520.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
003520.KS Stock Summary
Top 003520.KS Correlated Resources
003520.KS
Top 10 Correlated ETFs
003520.KS
Top 10 Correlated Stocks
003520.KS
In the News
003520.KS Financial details
Company Rating
Buy
Market Cap
550.5B
Income
-6.67B
Revenue
212.74B
Book val./share
564.68
Cash/share
-
Dividend
-
Dividend %
-
Employees
574
Optionable
No
Shortable
Yes
Earnings
08 May 2023
P/E
-78.85
Forward P/E
-
PEG
-0.16
P/S
2.47
P/B
5.27
P/C
-
P/FCF
-25.09
Quick Ratio
-
Current Ratio
1.9
Debt / Equity
1.04
LT Debt / Equity
-
-
-
EPS (TTM)
-37.2
EPS next Y
-
EPS next Q
-
EPS this Y
8599.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
0.11%
Revenue Q/Q
4.17%
EPS Q/Q
48.26%
-
-
-
-
SMA20
-15.48%
SMA50
-8.72%
SMA100
12.23%
Inst Own
-
Inst Trans
-
ROA
-3%
ROE
-7%
ROC
-0.05%
Gross Margin
30%
Oper. Margin
-4%
Profit Margin
-3%
Payout
-
Shs Outstand
182.89M
Shs Float
84.74M
-
-
-
-
Target Price
-
52W Range
2390.0-5670.0
52W High
-47.53%
52W Low
+24.48%
RSI
39
Rel Volume
0.47
Avg Volume
714.9K
Volume
334.01K
Perf Week
-1.16%
Perf Month
-19.27%
Perf Quarter
21.43%
Perf Half Y
8.78%
-
-
-
-
Beta
1.15345
-
-
Volatility
64.53%, 258.16%
Prev Close
-0.17%
Price
2975
Change
-1.33%
003520.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.07K | 1.02K | 1.21K | 1.14K | 1.07K | |
| Net income per share | 10.22 | -33.36 | 27.5 | -0.73 | -63.33 | |
| Operating cash flow per share | 17.25 | 6.97 | 50.75 | 79.27 | 45.75 | |
| Free cash flow per share | -42.9 | -18.77 | -5.88 | 44.8 | -16.14 | |
| Cash per share | 66.7 | 10.03 | 3.56 | 2.34 | 2.54 | |
| Book value per share | 654.98 | 610.23 | 632.89 | 625.68 | 573.48 | |
| Tangible book value per share | 612.33 | 597.44 | 620.79 | 617.12 | 565.6 | |
| Share holders equity per share | 654.98 | 610.23 | 632.89 | 625.68 | 573.48 | |
| Interest debt per share | 101.94 | 68.7 | 79.99 | 41.21 | 72.55 | |
| Market cap | 1644.08B | 1086.38B | 1212.58B | 1470.46B | 967.5B | |
| Enterprise value | 1658.06B | 1096.84B | 1226.56B | 1477.31B | 980.1B | |
| P/E ratio | 880.26 | -178.07 | 241.07 | -11.05K | -83.53 | |
| Price to sales ratio | 8.43 | 5.83 | 5.5 | 7.05 | 4.93 | |
| POCF ratio | 521.64 | 852.61 | 130.63 | 101.43 | 115.62 | |
| PFCF ratio | -209.77 | -316.4 | -1.13K | 179.48 | -327.74 | |
| P/B Ratio | 13.74 | 9.73 | 10.48 | 12.85 | 9.22 | |
| PTB ratio | 13.74 | 9.73 | 10.48 | 12.85 | 9.22 | |
| EV to sales | 8.5 | 5.88 | 5.56 | 7.09 | 5 | |
| Enterprise value over EBITDA | 168.28 | 4.17K | 71.95 | 178.54 | -149.48 | |
| EV to operating cash flow | 526.07 | 860.82 | 132.14 | 101.9 | 117.13 | |
| EV to free cash flow | -211.56 | -319.44 | -1.14K | 180.32 | -332.01 | |
| Earnings yield | 0 | -0.01 | 0 | 0 | -0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0.01 | 0 | |
| Debt to equity | 0.7 | 0.76 | 0.73 | 0.64 | 0.85 | |
| Debt to assets | 0.41 | 0.43 | 0.42 | 0.39 | 0.46 | |
| Net debt to EBITDA | 1.42 | 39.73 | 0.82 | 0.83 | -1.92 | |
| Current ratio | 3.04 | 2.88 | 2.8 | 3.27 | 1.86 | |
| Interest coverage | 6.54 | -8.02 | 0 | 1.51 | -66.41 | |
| Income quality | 1.69 | -0.21 | 1.85 | -108.91 | -0.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.06 | 0.06 | 0.07 | 0.07 | |
| Intangibles to total assets | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | -3.49 | -3.69 | -1.12 | -0.43 | -1.35 | |
| Capex to revenue | -0.06 | -0.03 | -0.05 | -0.03 | -0.06 | |
| Capex to depreciation | -1.66 | -0.71 | -1.35 | -0.81 | -1.53 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 388.17 | 676.76 | 625.8 | 101.23 | 903.97 | |
| ROIC | 0.01 | -0.01 | 0.03 | 0 | -0.06 | |
| Return on tangible assets | 0.01 | -0.03 | 0.03 | 0 | -0.06 | |
| Graham Net | -282.84 | -321.27 | -306.54 | -259.84 | -376.83 | |
| Working capital | 76.55B | 71.58B | 71.54B | 68.53B | 41.36B | |
| Tangible asset value | 111.86B | 109.27B | 113.54B | 112.87B | 103.44B | |
| Net current asset value | 29.82B | 25.18B | 26.64B | 25.01B | 478.24M | |
| Invested capital | 0.15 | 0.11 | 0.13 | 0.06 | 0.12 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 14.86B | 16.02B | 16.47B | 11.86B | 12.83B | |
| Average inventory | 42.4B | 44.26B | 51.9B | 53.7B | 45.54B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 36.84 | 56.37 | 35.38 | 27.26 | 41.17 | |
| Days of inventory on hand | 117.71 | 139.71 | 145.12 | 139.07 | 104.78 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 9.91 | 6.47 | 10.32 | 13.39 | 8.87 | |
| Inventory turnover | 3.1 | 2.61 | 2.52 | 2.62 | 3.48 | |
| ROE | 0.02 | -0.05 | 0.04 | 0 | -0.11 | |
| Capex per share | -60.16 | -25.74 | -56.63 | -34.47 | -61.89 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 270.42 | 294.83 | 288.07 | 294.83 | 307.11 | |
| Net income per share | -20.83 | -9.34 | -8 | -8 | -11.86 | |
| Operating cash flow per share | 46.67 | -10.71 | -50.32 | 37.3 | -7.01 | |
| Free cash flow per share | 29.4 | -37.05 | -89.47 | 25.98 | -18.37 | |
| Cash per share | 0 | 2.54 | 1.91 | 4.67 | 0 | |
| Book value per share | 571.71 | 573.48 | 569.3 | 576.59 | 564.68 | |
| Tangible book value per share | 571.71 | 565.6 | 563.08 | 563.09 | 564.68 | |
| Share holders equity per share | 571.71 | 573.48 | 569.3 | 576.59 | 564.68 | |
| Interest debt per share | 0 | 71.71 | 162.16 | 145.24 | -0.5 | |
| Market cap | 919.95B | 967.5B | 944.64B | 641.25B | 465.24B | |
| Enterprise value | 919.95B | 980.1B | 973.62B | 665.92B | 465.24B | |
| P/E ratio | -60.36 | -141.62 | -162.5 | -113.28 | -55.44 | |
| Price to sales ratio | 18.6 | 17.94 | 18.05 | 12.3 | 8.56 | |
| POCF ratio | 107.79 | -493.98 | -103.35 | 97.19 | -375.36 | |
| PFCF ratio | 171.09 | -142.8 | -58.12 | 139.52 | -143.18 | |
| P/B Ratio | 8.8 | 9.22 | 9.13 | 6.29 | 4.66 | |
| PTB ratio | 8.8 | 9.22 | 9.13 | 6.29 | 4.66 | |
| EV to sales | 18.6 | 18.18 | 18.6 | 12.77 | 8.56 | |
| Enterprise value over EBITDA | -389.74 | -864.7 | 2.25K | 1.75K | -191.48 | |
| EV to operating cash flow | 107.79 | -500.41 | -106.52 | 100.92 | -375.36 | |
| EV to free cash flow | 171.09 | -144.65 | -59.9 | 144.88 | -143.18 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0.01 | -0.01 | -0.02 | 0.01 | -0.01 | |
| Debt to equity | 0.77 | 0.85 | 0.96 | 1 | 1.04 | |
| Debt to assets | 0.43 | 0.46 | 0.49 | 0.5 | 0.51 | |
| Net debt to EBITDA | 0 | -11.11 | 66.95 | 64.7 | 0 | |
| Current ratio | 2.7 | 1.86 | 1.68 | 2.01 | 1.9 | |
| Interest coverage | 0 | -50.46 | -5.97 | -7.45 | 26.41 | |
| Income quality | -2.24 | 1.15 | 6.29 | -4.66 | 0.59 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.36 | 0.02 | 0.02 | 0.01 | 0.33 | |
| Research and developement to revenue | 0 | 0.06 | 0.06 | 0.06 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex to operating cash flow | -0.37 | 2.46 | 0.78 | -0.3 | 1.62 | |
| Capex to revenue | -0.06 | -0.09 | -0.14 | -0.04 | -0.04 | |
| Capex to depreciation | -1.75 | -2.68 | -3.94 | -1.07 | -1.01 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 517.67 | 347.13 | 320.11 | 322.16 | 388.19 | |
| ROIC | 0.07 | -0.01 | 0 | -0.01 | -0.01 | |
| Return on tangible assets | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Graham Net | -440.03 | -376.83 | -430.47 | -431.63 | -587.81 | |
| Working capital | 57.11B | 41.36B | 40.4B | 51.39B | 48B | |
| Tangible asset value | 104.56B | 103.44B | 102.29B | 99.61B | 99.89B | |
| Net current asset value | 10.32B | 478.24M | -160.55M | 189.26M | -2.72B | |
| Invested capital | 0 | 0.12 | 0.28 | 0.25 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 6.93B | 7.79B | 15.55B | 18.81B | 11.04B | |
| Average inventory | 24.8B | 19.83B | 41.03B | 45.98B | 24.78B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 37 | 38.51 | 54.76 | 0 | |
| Days of inventory on hand | 0 | 94.18 | 105.21 | 122.87 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 2.43 | 2.34 | 1.64 | 0 | |
| Inventory turnover | 0 | 0.96 | 0.86 | 0.73 | 0 | |
| ROE | -0.04 | -0.02 | -0.01 | -0.01 | -0.02 | |
| Capex per share | -17.27 | -26.34 | -39.16 | -11.32 | -11.36 |
003520.KS Frequently Asked Questions
What is Yungjin Pharm. Co., Ltd. stock symbol ?
Yungjin Pharm. Co., Ltd. is a KR stock and trading under the symbol 003520.KS
What is Yungjin Pharm. Co., Ltd. stock quote today ?
Yungjin Pharm. Co., Ltd. stock price is $2975 today.
Is Yungjin Pharm. Co., Ltd. stock public?
Yes, Yungjin Pharm. Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 714.9K
- Market Capitalization 550.5B
- Employee 574
- CEO Mr. Chae-Joon Lee
- Headquarters Seoul,KR
- IPO Date 2001-01-08
-
Website
https://www.yungjin.co.kr 
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.
